

No data available
No data available
No data available
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 562.01 | 482.10 | 647.39 | 681.33 | 663.90 |
| Total Expenses | 516 | 454.45 | 569.20 | 591.65 | 545.08 |
| Profit Before Tax | 46.01 | -16.68 | 78.18 | 89.68 | 118.82 |
| Profit After Tax | 42.93 | -14.33 | 63.53 | 71.39 | 83.11 |
| Operating Profit After Depreciation | 73.91 | 57.33 | 95.74 | 102.31 | 127.12 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 238.45 | 254.57 | 367.07 | 269.74 | 208.13 |
| Total Non Current Assets | 347.64 | 360.59 | 397.26 | 322.79 | 267.30 |
| Total Current Assets | 485.40 | 404.54 | 500.40 | 398.31 | 258.33 |
| Total Assets | 833.05 | 765.13 | 897.66 | 721.10 | 525.63 |
| Total Shareholder's Fund | 466.16 | 278.36 | 367.69 | 328.49 | 258.41 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 21.62 | 92.29 | -22.19 | 0.69 | 43.56 |
| Net Cash Used In Investing Activities | -14.82 | -11.24 | -93.43 | -74.80 | -108.93 |
| Net Cash Used In Financing Activities | -6.38 | -96.60 | 131.37 | 61.85 | 75.46 |
No data available
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 153.06 | 161.22 | 147.91 | 148.84 | 154.47 |
| Total Expenses | 133.82 | 130.97 | 122.31 | 124.66 | 143.14 |
| Profit Before Tax | -24.25 | 18.82 | 14.61 | 14.19 | 11.29 |
| Profit After Tax | -22.85 | 15.67 | 11.11 | 11.83 | 11.18 |
| Operating Profit after Depreciation | 22.20 | 31.90 | 27.25 | 25.06 | 24.90 |
₹1.0/Share
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,794.30 | ₹4,30,512.67 |
| Divis Laboratories Ltd | ₹6,651.25 | ₹1,76,569.79 |
| Torrent Pharmaceuticals Ltd | ₹4,570 | ₹1,54,669.57 |
| Cipla Ltd | ₹1,383 | ₹1,11,725.01 |
| Zydus Lifesciences Ltd | ₹1,105.65 | ₹1,11,254.26 |
| Fund Name | AUM |
|---|---|
| HDFC Pharma and Healthcare Fund | 0.73% |
| Bandhan BSE Healthcare Index Fund | 0.03% |
Bajaj Healthcare fell 1.10% to Rs 336 after the company reported a standalone net loss of Rs 22.85 crore in Q4 FY26, compared with a net profit of Rs 11.17 crore posted in Q4 FY25.
11 May 2026, 09:34 am
Bajaj Healthcare reported a standalone net loss of Rs 22.85 crore in Q4 FY26, compared with a net profit of Rs 11.17 crore posted in Q4 FY25.
09 May 2026, 11:13 am
Of Rs 1.5 per share
09 May 2026, 09:46 am
On 8 May 2026
04 May 2026, 10:38 am
On 18 March 2026
14 Mar 2026, 10:01 am

Get started with us today and
start building your wealth journey
*By clicking, I agree to the T&C and Whatsapp updates.

Get started with us today and
start building your wealth journey
*By clicking, I agree to the T&C and Whatsapp updates.

Congratulations,
Your Digital savings bank account opening journey is complete.